The D.C. in Washington D.C. stands for District of Columbia, of course. But it also stands for “Darn Cold” as temperatures reached near freezing levels. Luckily for the attendees of the Society for Neuroscience Conference on November 15, Dr. Richard Gordon brought warmth, enthusiasm, and charm to his presentation on RRx-001/nibrozetone as a potential treatment for neurodegenerative diseases like Parkinson’s and Amyotrophic Lateral Sclerosis (ALS)/Motor Neurone Disease (MND).
Dr. Gordon began his presentation with evidence that implicates NLRP3 inflammasome activation as a driver of the neuroinflammation that is behind the initiation and progression of neurodegenerative diseases like Parkinson’s and ALS/MND.
From there he presented robust in vitro and in vivo data that RRx-001/nibrozetone, a late stage clinical candidate, not only potently inhibits the NLRP3 inflammasome throughout the central nervous system (CNS) but also the antioxidant transcription factor, Nrf2.
At the end of his talk, one of the attendees commented that “you presented a lot of data cleanly and clearly in a short amount of time. Hats off to you”.
Hats off indeed.
Had we been wearing hats or gloves or scarves, Dr. Gordon’s warm and engaging talk would have probably made it possible to remove them in the otherwise cold conference room.